Smartphone app to help start hepatitis B treatment
Part of Digestive system, Infections clinical trials.
This study tests whether a smartphone app with artificial intelligence can help people with diagnosed hepatitis B who haven't started treatment yet to begin taking antiviral medications. The app provides personalized support and information to encourage treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B (confirmed by blood test showing HBsAg for at least 6 months)
- You have never taken hepatitis B antiviral medications, or stopped them at least 6 months ago
- You can use a smartphone by yourself or with family help
- You are 18 years old or older
- You are willing to sign a consent form and complete study follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a smartphone app called HBVCare helps patients with chronic hepatitis B stick to their treatment plans. Researchers will track how well the app helps patients take their medicines on time and understand what makes treatment adherence easier or harder.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.